It is therefore hypothesised that immunomodulatory drugs, such as tocilizumab (IL6 receptor, IL6R, inhibitor), canakinumab (IL1β inhibitor) or colchicine (β-tubulin inhibitor) may prove effective for the management of AS. Here, IL6R is linked to aortic stenosis.